Avalanche Biotechnologies Acquires Gene Firm In $105.6 Million Deal
"We are seeking to expand our pipeline further through additional licenses and acquisitions that complement our expertise in vector development and optimization platforms, process development and manufacturing," says the CEO of Avalanche Biotechnologies.
The San Francisco Business Times:
Bay Area Biotech Buys Gene Therapy Firm After Stock Craters
Avalanche Biotechnologies has agreed to acquire Paris-based Annapurna Therapeutics in a $105.6 million deal that expands its gene therapy pipeline. The Menlo Park company led by Paul Cleveland said the deal will combine his company's four gene therapy programs for ophthalmic diseases with Annapurna’s gene therapies for Alpha1-antitrypsin (A1AT) deficiency, cardiomyopathy associated with Friedreich’s ataxia, hereditary angioedema, and severe allergies. (Schubarth, 2/1)